Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novan Inc (NOVN)

Novan Inc (NOVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,459
  • Shares Outstanding, K 141,514
  • Annual Sales, $ 4,900 K
  • Annual Income, $ -30,640 K
  • 60-Month Beta 0.01
  • Price/Sales 18.11
  • Price/Cash Flow N/A
  • Price/Book 24.87
Trade NOVN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year 0.11
  • Growth Rate Est. (year over year) -154.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6322 +115.12%
on 12/22/20
1.5700 -13.38%
on 01/19/21
+0.6810 (+100.29%)
since 12/21/20
3-Month
0.4350 +212.64%
on 11/02/20
1.5700 -13.38%
on 01/19/21
+0.8441 (+163.62%)
since 10/21/20
52-Week
0.2150 +532.56%
on 02/28/20
1.5700 -13.38%
on 01/19/21
+0.6888 (+102.62%)
since 01/21/20

Most Recent Stories

More News
Thinking about buying stock in Sundial Growers, Charah Solutions, Sorrento Therapeutics, Zomedica, or Novan?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, CHRA, SRNE, ZOM, and NOVN.

ZOM : 1.0000 (-1.96%)
NOVN : 1.3600 (+3.82%)
SNDL : 0.6612 (-2.88%)
SRNE : 9.98 (-0.50%)
CHRA : 4.26 (-0.93%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Novan, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

, /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board...

NOVN : 1.3600 (+3.82%)
Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the January...

NOVN : 1.3600 (+3.82%)
Thinking about buying stock in BioNano Genomics, Ocugen, Acasti Pharma, Novan, or Transenterix?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNGO, OCGN, ACST, NOVN, and TRXC.

TRXC : 3.24 (-6.63%)
BNGO : 8.27 (+2.73%)
NOVN : 1.3600 (+3.82%)
OCGN : 2.25 (+0.90%)
ACST : 0.8348 (+10.39%)
Thinking about buying stock in Novan, Fubotv, Zomedica, Riot Blockchain, or Ocugen?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, FUBO, ZOM, RIOT, and OCGN.

ZOM : 1.0000 (-1.96%)
NOVN : 1.3600 (+3.82%)
OCGN : 2.25 (+0.90%)
RIOT : 19.35 (-13.15%)
FUBO : 35.50 (+17.74%)
Recent Challenges Demand Innovative Approaches to Surface Disinfections

, /PRNewswire/ -- Due to the pandemic's rapid spread earlier this year, the U.S. EPA (Environment Protection Agency) accelerated its review process of submissions by disinfectant manufacturers. The EPA...

NOVN : 1.3600 (+3.82%)
OPTI : 0.1430 (+24.35%)
TRVN : 2.16 (+0.47%)
VBIV : 3.08 (-6.53%)
AMRX : 4.86 (+2.32%)
Results from Pivotal, Phase 3 Trial for SECUADO(R) (asenapine) Published in Journal of Clinical Psychiatry

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced publication of the results from a pivotal, phase 3 trial, which showed that SECUADO(R) (asenapine)...

HTSUF : 42.0500 (unch)
NOVN : 1.3600 (+3.82%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Novan, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

, /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board...

NOVN : 1.3600 (+3.82%)
Women Health Market Size Business Growth, Global Market Analysis, Share, Research, and Forecast to 2025 Research Reports World

Posted on Dec 14 2020 10:01 AM

ABT : 112.95 (+0.05%)
AGN : 193.02 (+0.02%)
AMGN : 252.03 (-0.13%)
AZN : 52.55 (+0.59%)
BAYRY : 16.1800 (-0.92%)
LLY : 202.35 (+0.54%)
GSK : 37.78 (-0.63%)
NBIX : 115.00 (+3.53%)
NVS : 96.88 (-0.04%)
NOVN : 1.3600 (+3.82%)
NVO : 72.52 (+0.75%)
PFE : 36.48 (-0.05%)
RDUS : 22.00 (+1.57%)
TXMD : 1.4400 (+0.70%)
VRX.TO : 30.80 (-3.33%)
Thinking about buying stock in Sundial Growers, Novan, Marathon Oil, Advanced Micro Devices, or Boeing?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, NOVN, MRO, AMD, and BA.

NOVN : 1.3600 (+3.82%)
SNDL : 0.6612 (-2.88%)
AMD : 91.53 (+3.13%)
BA : 207.41 (-1.91%)
MRO : 8.25 (-4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through...

See More

Key Turning Points

3rd Resistance Point 1.8033
2nd Resistance Point 1.6467
1st Resistance Point 1.5033
Last Price 1.3600
1st Support Level 1.2033
2nd Support Level 1.0467
3rd Support Level 0.9033

See More

52-Week High 1.5700
Last Price 1.3600
Fibonacci 61.8% 1.0524
Fibonacci 50% 0.8925
Fibonacci 38.2% 0.7326
52-Week Low 0.2150

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar